Shopping Cart 0
Cart Subtotal
AED 0

National Institute on Aging - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

National Institute on Aging (NIA), a subsidiary of National Institutes of Health is a healthcare institute that offers health and aging care services. The institute conducts research on aging through researchers and the international community of scientists. Its services comprise research, extramural program, research funding, training, intramural program, basic, clinical research and health information. NIA operates various departments such as geriatrics and clinical gerontology, neurosciences, extramural activities, scientific review, aging biology, behavioral and social research, among others. The institute also offers consumer-oriented information on topics related to older people and their families. NIA is headquartered in Bethesda, Maryland, the US.

National Institute on Aging-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

National Institute on Aging, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11

Licensing Agreements 12

Peptron Enters into Licensing Agreement with National Institute on Aging 12

Elixirgen Enters into License Agreement with National Institute on Aging 13

National Institute on Aging-Key Competitors 14

National Institute on Aging-Key Employees 15

National Institute on Aging-Locations And Subsidiaries 16

Head Office 16

Recent Developments 17

Government and Public Interest 17

Jul 30, 2018: Advancing the Search for Antibodies to Treat Alzheimer's Disease 17

Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 18

Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 20

Jul 09, 2018: Senolytic drugs reverse damage caused by senescent cells in mice 21

Jun 26, 2018: New tests aim to support improvements in care for those dealing with delirium 22

Jun 21, 2018: Unusually High Levels of Herpesviruses Found in the Alzheimer's Disease Brain, Mount Sinai Researchers Report 23

Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 25

May 31, 2018: City of Hope receives USD 2 million grant to promote critical research on aging and cancer 26

May 29, 2018: Tgen, Northwestern University Study Of 'Superagers' Offers Genetic Clues To Their Cognitive Performance 27

May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 28

Apr 17, 2018: Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer's Disease 29

Apr 10, 2018: New biological research framework for Alzheimer's to spur discovery 30

Feb 06, 2018: Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease 32

Jan 09, 2018: Researchers Receive USD 2.8 Million to Repurpose FDA-approved Drugs to Treat Alzheimer's Disease 33

Nov 16, 2017: Researchers identify first brain training exercise positively linked to dementia prevention 35

Nov 07, 2017: OMRF researcher receives Alzheimer's grant 36

Nov 06, 2017: Higher brain glucose levels may mean more severe Alzheimer's 37

Nov 02, 2017: Study explores nicotine patch to treat mild cognitive impairment 38

Oct 27, 2017: Applied BioMath awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia 40

Oct 26, 2017: Study shows brain structures make some people resilient to Alzheimer's disease 41

Oct 17, 2017: Cleveland Clinic Earns NIH Grant to Study Benefits of Exercise in People at Risk for Alzheimer's Disease 43

Oct 10, 2017: UC Irvine: Effort to Create Mouse That More Closely Mirrors Human Alzheimer's Wins Federal Grant 44

Oct 09, 2017: IU awarded USD 7.6 million grant to establish groundbreaking study of early-onset Alzheimer's disease 45

Oct 02, 2017: Cleveland Clinic, The MetroHealth System Receive Grant to Enhance Heart Disease Risk Calculators 46

Sep 20, 2017: Rethink on beta blockers for heart attack survivors who take their other heart medication 47

Sep 18, 2017: New USD 5.4M grant funds JAX studies of 'cognitive resilience' to Alzheimer's disease 48

Sep 15, 2017: Afraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug Discovery 49

Sep 07, 2017: Oligomerix Awarded National Institute on Aging SBIR Grant for Development of Alzheimer's Disease Specific Biomarker 50

Aug 14, 2017: Brain Scan Study Adds to Evidence That Lower Brain Serotonin Levels are Linked to Dementia 51

May 14, 2017: New USD 2.7M Federal Grant Awarded To Jax Alzheimer's Researcher 53

May 14, 2017: New USD 3.2M federal grant awarded to JAX Alzheimers researcher 54

Apr 13, 2017: Researcher Receives Five-Year Grant From the National Institute on Aging at the National Institutes of Health 55

Product News 57

Jul 09, 2018: Senolytics Improve Health, Extend life: Preclinical research findings 57

Other Significant Developments 58

Sep 16, 2018: Daily low-dose aspirin found to have no effect on healthy life span in older people 58

Jul 04, 2018: Pathway of Alzheimer's degeneration discovered 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

National Institute on Aging, Pharmaceuticals & Healthcare, Key Facts 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11

Peptron Enters into Licensing Agreement with National Institute on Aging 12

Elixirgen Enters into License Agreement with National Institute on Aging 13

National Institute on Aging, Key Competitors 14

National Institute on Aging, Key Employees 15

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

National Institute on Aging, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

National Institute on Aging (NIA), a subsidiary of National Institutes of Health is a healthcare institute that offers health and aging care services. The institute conducts research on aging through researchers and the international community of scientists. Its services comprise research, extramural program, research funding, training, intramural program, basic, clinical research and health information. NIA operates various departments such as geriatrics and clinical gerontology, neurosciences, extramural activities, scientific review, aging biology, behavioral and social research, among others. The institute also offers consumer-oriented information on topics related to older people and their families. NIA is headquartered in Bethesda, Maryland, the US.

National Institute on Aging-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

National Institute on Aging, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11

Licensing Agreements 12

Peptron Enters into Licensing Agreement with National Institute on Aging 12

Elixirgen Enters into License Agreement with National Institute on Aging 13

National Institute on Aging-Key Competitors 14

National Institute on Aging-Key Employees 15

National Institute on Aging-Locations And Subsidiaries 16

Head Office 16

Recent Developments 17

Government and Public Interest 17

Jul 30, 2018: Advancing the Search for Antibodies to Treat Alzheimer's Disease 17

Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 18

Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 20

Jul 09, 2018: Senolytic drugs reverse damage caused by senescent cells in mice 21

Jun 26, 2018: New tests aim to support improvements in care for those dealing with delirium 22

Jun 21, 2018: Unusually High Levels of Herpesviruses Found in the Alzheimer's Disease Brain, Mount Sinai Researchers Report 23

Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 25

May 31, 2018: City of Hope receives USD 2 million grant to promote critical research on aging and cancer 26

May 29, 2018: Tgen, Northwestern University Study Of 'Superagers' Offers Genetic Clues To Their Cognitive Performance 27

May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 28

Apr 17, 2018: Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer's Disease 29

Apr 10, 2018: New biological research framework for Alzheimer's to spur discovery 30

Feb 06, 2018: Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease 32

Jan 09, 2018: Researchers Receive USD 2.8 Million to Repurpose FDA-approved Drugs to Treat Alzheimer's Disease 33

Nov 16, 2017: Researchers identify first brain training exercise positively linked to dementia prevention 35

Nov 07, 2017: OMRF researcher receives Alzheimer's grant 36

Nov 06, 2017: Higher brain glucose levels may mean more severe Alzheimer's 37

Nov 02, 2017: Study explores nicotine patch to treat mild cognitive impairment 38

Oct 27, 2017: Applied BioMath awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia 40

Oct 26, 2017: Study shows brain structures make some people resilient to Alzheimer's disease 41

Oct 17, 2017: Cleveland Clinic Earns NIH Grant to Study Benefits of Exercise in People at Risk for Alzheimer's Disease 43

Oct 10, 2017: UC Irvine: Effort to Create Mouse That More Closely Mirrors Human Alzheimer's Wins Federal Grant 44

Oct 09, 2017: IU awarded USD 7.6 million grant to establish groundbreaking study of early-onset Alzheimer's disease 45

Oct 02, 2017: Cleveland Clinic, The MetroHealth System Receive Grant to Enhance Heart Disease Risk Calculators 46

Sep 20, 2017: Rethink on beta blockers for heart attack survivors who take their other heart medication 47

Sep 18, 2017: New USD 5.4M grant funds JAX studies of 'cognitive resilience' to Alzheimer's disease 48

Sep 15, 2017: Afraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug Discovery 49

Sep 07, 2017: Oligomerix Awarded National Institute on Aging SBIR Grant for Development of Alzheimer's Disease Specific Biomarker 50

Aug 14, 2017: Brain Scan Study Adds to Evidence That Lower Brain Serotonin Levels are Linked to Dementia 51

May 14, 2017: New USD 2.7M Federal Grant Awarded To Jax Alzheimer's Researcher 53

May 14, 2017: New USD 3.2M federal grant awarded to JAX Alzheimers researcher 54

Apr 13, 2017: Researcher Receives Five-Year Grant From the National Institute on Aging at the National Institutes of Health 55

Product News 57

Jul 09, 2018: Senolytics Improve Health, Extend life: Preclinical research findings 57

Other Significant Developments 58

Sep 16, 2018: Daily low-dose aspirin found to have no effect on healthy life span in older people 58

Jul 04, 2018: Pathway of Alzheimer's degeneration discovered 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

National Institute on Aging, Pharmaceuticals & Healthcare, Key Facts 2

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute on Aging, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11

Peptron Enters into Licensing Agreement with National Institute on Aging 12

Elixirgen Enters into License Agreement with National Institute on Aging 13

National Institute on Aging, Key Competitors 14

National Institute on Aging, Key Employees 15

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

National Institute on Aging, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.